Mark A. Lewis, MD

Articles

The Evolution of ctDNA Assays in CRC

April 30th 2025

Scott Kopetz, MD, PhD, FACP, and Mark A. Lewis, MD, discuss how ctDNA assays have improved MRD detection in CRC.

How ctDNA Is Informing Ongoing Trials in CRC

April 30th 2025

Scott Kopetz, MD, PhD, FACP, and Mark A. Lewis, MD, discuss ongoing research in CRC utilizing ctDNA.

Talking to Patients With CRC About ctDNA

April 30th 2025

Scott Kopetz, MD, PhD, FACP, and Mark A. Lewis, MD, discuss how to approach conversations about ctDNA with patients with CRC.

Implications From the BESPOKE CRC Study Evaluating ctDNA in Stage II-III CRC

April 30th 2025

Scott Kopetz, MD, PhD, FACP, and Mark A. Lewis, MD, discuss findings for ctDNA in stage II/III CRC from the BESPOKE CRC trial.

CIRCULATE-Japan: Diving Into ctDNA and DFS Data in Stage II-IV CRC

April 30th 2025

Scott Kopetz, MD, PhD, FACP, and Mark A. Lewis, MD, on data from the GALAXY arm of CIRCULATE-Japan for ctDNA in stage II to IV CRC.

Why ctDNA Remains a Focal Point in CRC Research

April 30th 2025

Scott Kopetz, MD, PhD, FACP, and Mark A. Lewis, MD, on why ctDNA remains a focus of research in colorectal cancer.

Anticipating Key Studies and Pipeline Treatments in mCRC Landscape

April 11th 2024

The experts provide their final thoughts surrounding the impact of prospective trials and therapy regimens for treating patients with refractory mCRC.

Unmet Needs Surrounding mCRC Treatment

April 11th 2024

Key opportunities to improve the mCRC treatment landscape are illustrated by the expert panelists.

Data Surrounding Treatment for MSI-high Patients from ASCO 2024

April 4th 2024

Dr Kim offers key perspective for MSI-high patients based on data presented at ASCO 2024.

Real-World Data Surrounding Sequencing Strategies for Refractory mCRC

April 4th 2024

Multiple abstracts from ESMO 2023, including a focus on tumor location, are highlighted.

Treatment Sequencing for Refractory mCRC and SUNLIGHT Study Analysis

March 28th 2024

Data presented at ESMO 2023 and ASCO GI 2024 highlight the impact of prior therapy, including VEGF inhibitors or fluoropyrimidine, on mCRC treatment approach.

Considerations for Platinum-based Therapy

March 28th 2024

Key factors, particularly neuropathy, drive the discussion for platinum-based therapy for patients with non-refractory mCRC.

Identifying Ideal Candidates for Triplet Therapy in mCRC Treatment

March 21st 2024

Considerations for patients to receive aggressive mCRC therapy regimens are navigated by the panelists.

Fatigue Associated with Bevacizumab, Fruquintinib, TAS-102 Therapies

March 21st 2024

Side effect profiles driven by fruquintinib use are discussed.

Camidge and Lewis Discuss the Perspective of Being Both a Patient and Physician

March 14th 2024

Drs Camidge and Lewis discuss how Dr Lewis’ MEN-1 diagnosis has affected his professional life and the importance of seeking patient perspectives.

Consideration for Fruquintinib Dosing and Titration

March 14th 2024

Mark A Lewis, MD, and Scott Paulson, MD, share their experiences utilizing fruquintinib.

Utilizing RWE to Derive Optimal Treatment Strategy for Refractory mCRC

March 14th 2024

Richard Kim, MD, discusses the significance of real-world evidence when selecting treatment sequencing strategy.

Dose Modifications and Tolerability Associated with mCRC Treatment Regimens

March 7th 2024

Managing dose adjustments and tolerability in metastatic colorectal cancer (mCRC) treatment regimens for optimal efficacy is underscored.

FRESCO-2 Study Highlights

March 7th 2024

Medical experts provide key takeaways and impacts from the FRESCO-2 study.

Compounding Impact of TAS-102 and Bevacizumab in mCRC Treatment

February 29th 2024

Marwan G Fakih, MD, drives a discussion highlighting a significant combination therapy in mCRC treatment.